Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.
about
Pharmacological interventions for reducing weight gain in schizophreniaComorbidity Factors and Brain Mechanisms Linking Chronic Stress and Systemic IllnessDetection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate?The impact of leptin on perinatal development and psychopathologyPharmacological mechanisms underlying the association of antipsychotics with metabolic disordersOlanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylationWeight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management.Antipsychotic drugs and obesity.Peptides from adipose tissue in mental disordersRegulation of interleukin-6 and leptin in schizophrenia patients: a preliminary analysis.New wine in old bottle: late-life psychosisAntipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis.Relationships between Brain Structure and Metabolic Changes in Schizophrenia Patients Treated with Olanzapine: A Voxel-Based Morphometric Study.Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis.Negative Correlation between Serum S100B and Leptin Levels in Schizophrenic Patients During Treatment with Clozapine and Risperidone: Preliminary EvidencePharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complicationsRelationships between serum leptin level and severity of positive symptoms in schizophrenia.Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine.Atypical antipsychotic-induced weight gain: insights into mechanisms of action.The metabolic syndrome in schizophrenia: is inflammation a contributing cause?Genetics of antipsychotic-induced weight gain: update and current perspectives.The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity.Atypical antipsychotics and effects on feeding: from mice to men.Genetic Determinants of Clozapine-Induced Metabolic Side Effects.Overexpression of Insig-2 inhibits atypical antipsychotic-induced adipogenic differentiation and lipid biosynthesis in adipose-derived stem cells.Interleukin-6 in Schizophrenia-Is There a Therapeutic Relevance?Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes.Contribution of baseline body mass index and leptin serum level to the prediction of early weight gain with atypical antipsychotics in schizophrenia.A weight-independent association between atypical antipsychotic medications and obstructive sleep apnea.The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study.Association between antipsychotic treatment and leptin levels across multiple psychiatric populations: An updated meta-analysis.Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment.Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: A 7-month follow-up study.Body and liver fat content and adipokines in schizophrenia: a magnetic resonance imaging and spectroscopy study.
P2860
Q24194410-A1641E10-595C-4DE7-94A7-3A3C700C0F01Q26765501-49C56006-C31C-48A9-9561-1BDEF6710BCAQ26864342-FC082BA4-EC4F-43B8-A328-65BE6FD82944Q26865196-72997E71-DC42-4037-9926-AC9A82729F38Q26999668-7B5FE573-D6E4-4720-93F7-5E2CAA4F9D15Q28478539-F78B12F6-74F1-4543-BA90-ABD258896CB5Q34543946-44AD72CA-3B15-40A9-9867-AF90741E8025Q34648940-0C0A2C1D-B980-4C10-ACF4-D3979BCDF9B9Q34761266-FC8A6F26-82E2-417F-BE8B-FE2D458F1EC8Q34942662-CE0270C8-3336-4EA8-BFC8-84447EA0FF0DQ34976609-5023552E-E6D1-41EF-A2BF-71356D78EE8CQ35566086-ECD74956-9B86-427F-B298-31EF38466AE5Q36169521-F466F917-D650-4C94-8CEC-3D8A15EB8854Q36852489-9C4777D9-C5B0-48AE-A5F9-D44620C26E75Q37178192-81AFCCE6-73B4-4F36-B399-3E1B27D81700Q37220366-8556D37B-901E-4922-A98F-511C781A96C2Q37606046-A98C9983-6CCA-454B-B7CF-8869E9F4604FQ37697285-2AAC5969-E82C-4367-BA62-F13697F69EBAQ37963571-BF73FA8A-2ACC-422A-8380-9DF7E3BE7A45Q37999568-B8A3EC62-8736-4BB8-8A2E-A884A2D35340Q38166456-4E80897B-A3EC-491F-B22C-28B501D716B7Q38170310-D51F9543-978F-49B8-BF9F-9ECB8D2A20F0Q38850666-7294DA5A-07AB-4DB5-A16E-C43486AAF340Q40562486-36F59620-37FB-47CD-A640-8E4F6E8D11E4Q41541889-FFEF4FE5-666C-40F5-AA1F-C453AB5260B5Q47155489-9DED70E0-6214-49D7-858C-20A072640C0FQ47165661-E7417B0A-2FAA-4929-A11E-4B76D7F2095FQ47182858-50E108DD-134B-432E-ABB7-0EF26BFE2FEFQ47200313-9E25242B-5880-4896-807A-6FA6C625DB53Q47302269-D9C38869-5E0B-426B-BC4F-8ED85C239142Q47605999-74BD6A58-0FC8-4F64-AAA1-D26FE443B9E9Q50156396-3B54BE6A-E219-4049-B952-FEA5B4919F7BQ51435215-CC6CA2E1-FC7A-44B3-8C13-E302F6297BB5Q53118076-2D16EB13-4B13-440C-9568-083AEE405C31
P2860
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.
@en
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.
@nl
type
label
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.
@en
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.
@nl
prefLabel
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.
@en
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.
@nl
P2093
P2860
P1476
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.
@en
P2093
Jonathan M Meyer
Sunder Mudaliar
P2860
P356
10.1016/J.SCHRES.2007.11.026
P407
P577
2008-01-18T00:00:00Z